Cardiol Therapeutics (DE:CT9)
FRANKFURT:CT9
CT9 Stock Chart & Stats
€1.12
<€0.01(0.43%)
At close: 4:00 PM EST
€1.12
<€0.01(0.43%)
Day’s Range― - ―
52-Week Range€0.73 - €1.36
Previous CloseN/A
Volume1.00K
Average Volume (3M)118.00
Market Cap
€103.78M
Enterprise Value€161.51M
Total Cash (Recent Filing)€27.67M
Total Debt (Recent Filing)€116.41K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding115,272,240
10 Day Avg. Volume215
30 Day Avg. Volume118
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.34Price Target Upside555.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthExtremely low debt reduces refinancing and solvency risk and gives management structural flexibility to prioritize R&D spend. Over a multi-month horizon this lowers immediate liquidity stress and preserves optionality to time financings or strategic partnerships rather than being forced into distressed funding.
Focused Clinical-stage PipelineA concentrated pipeline targeting anti-inflammatory and anti-fibrotic cardiovascular indications creates clear strategic focus and potential for high-value outcomes if clinical milestones are met. This specialization supports durable R&D expertise and a coherent go-to-market path if the candidates progress to late-stage studies or partnerships.
Narrowing Of Cash OutflowsA trend toward reduced cash outflow signals improving operational discipline and potentially more efficient trial/resource allocation. If sustained, this durable improvement increases the chance management can fund nearer-term milestones with less dilution or extended runway through partnerships or milestone-based payments.
Bears Say
Pre-revenue Status And Sizable LossesLack of commercial revenue means the business is fully dependent on external capital to progress clinical programs. Sustained losses erode equity and limit operating leverage; absent near-term commercialization, this structural profile increases execution and financing risk over the next several months.
Persistent Heavy Cash BurnMaterial negative operating and free cash flow creates ongoing reliance on capital raises or partnerships to fund trials. Even with some improvement, persistent burn constrains strategic choices, raises dilution risk, and can delay or scale back development programs if additional funding is not secured.
Funding/dilution Risk And Equity ErosionThe company must likely access external capital before generating revenue; repeated financings can dilute shareholders and weaken incentives. Reported declining equity and deeply negative returns on equity reflect value erosion that can persist absent clinical success or non-dilutive financing, affecting long-term investor returns.
Cardiol Therapeutics News
CT9 FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was €0.73 and its highest was €1.36 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is €103.78M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 62 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 115,272,240 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in DE:CT9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
-229.16%
Trailing 12-Months
Asset Growth
27.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CT9 Stock 12 Month Forecast
Average Price Target
€7.34
▲(555.01% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---